My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Lupin Ltd Research Report - 11th Nov 2016

Pharmaceutical | Published on Nov 11th 2016

IT

Lupin posted results lower than expected. Sales came in at Rs4,212cr vs. Rs4,300cr expected, registering a yoy growth of 31.9%, mainly aided by exports. The sales growth was driven by Formulations sales (Rs3,919.3cr), posting a yoy growth of 37.1%; while API sales (Rs291.9cr) posted a yoy de-growth of 12.3%. On the operating front, the EBITDA margin came in at 22.5% vs. 24.3% expected vs. 16.5% in 2QFY2016. The OPM contracted in spite of the gross margin expansion, which came in at 70.5% vs. 70.5% in 2QFY2016, on the back of 35.9% and 32.8% yoy growth in the employee and other expenses, respectively. Consequently, the Adj. PAT came in at Rs662cr vs. Rs758cr expected vs. Rs420cr in 2QFY2016, a yoy growth of 57.8%. We maintain our Buy rating on the stock.

Download Full Report

Accumulate

CMP 1,493
Target Price 1,809
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Promoter47.0
Foreign33.0
Public & Others10.0
Institution9.0
Corporate1.0
Grand Total100.0

Trade Securely

AngelEye

Portfolio Tracking & Trading Application View Demo